Article info

PDF

Original article
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Authors

  • Timothy M Nywening Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Brian A Belt Department of Surgery, University of Rochester Medical Center, Rochester, New York, USATumor Biology Program, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute; University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Darren R Cullinan Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Roheena Z Panni Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Booyeon J Han Department of Surgery, University of Rochester Medical Center, Rochester, New York, USATumor Biology Program, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute; University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Dominic E Sanford Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Ryan C Jacobs Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Jian Ye Department of Surgery, University of Rochester Medical Center, Rochester, New York, USATumor Biology Program, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute; University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • Ankit A Patel Department of Surgery, University of Rochester Medical Center, Rochester, New York, USATumor Biology Program, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute; University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  • William E Gillanders Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Ryan C Fields Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • David G DeNardo Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USADepartment of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, Missouri, USADepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • William G Hawkins Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • Peter Goedegebuure Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USAAlvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA PubMed articlesGoogle scholar articles
  • David C Linehan Department of Surgery, University of Rochester Medical Center, Rochester, New York, USATumor Biology Program, University of Rochester Medical Center, Rochester, New York, USAWilmot Cancer Institute; University of Rochester Medical Center, Rochester, New York, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr David C Linehan, University of Rochester Medical Center, Rochester, New York, USA; David_Linehan{at}urmc.rochester.edu
View Full Text

Citation

Nywening TM, Belt BA, Cullinan DR, et al
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

Publication history

  • Received 8 January 2017
  • Revised 9 October 2017
  • Accepted 10 October 2017
  • Published online 1 December 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.